Posted on 09/03/2010 in Pharmaceutical Company Product News GlaxoSmithKline has opened a new facility in order to assist with a worldwide programme to combat lymphatic filariasis (LF), or elephantiasis.
The pharmaceutical company has dedicated the site in Nashik, India to the production of albendazole, which is used as part of a combination treatment utilised by the World Health Organization in fight against the disease.
This facility will allow for the supply of 300 million treatments of albendazole per year, which means it represents the largest drug donation programme in pharmaceutical industry history.
Andrew Witty, GlaxoSmithKline's chief executive officer, expressed pride at playing a major part in a scheme which hopes to eradicate the illness completely by 2020.
He said: "Thirty years ago, scientific breakthroughs led to the eradication of smallpox. Today we have hope that another disease, lymphatic filariasis, can be consigned to the history books."
Last month, the healthcare firm received an endorsement from Europe's Committee for Medicinal Products for Human Use for approval of Tyverb and Votrient, two potentially promising cancer drugs.Other news stories from 09/03/2010
Read more in the Zenopa News Archive
How this news is generated
|
